Bruker Corporation and TOFWERK AG announced a strategic partnership for high-speed, ultra-sensitive applied and industrial analytical solutions, in conjunction with a Bruker minority investment in TOFWERK. The partnership provides a basis for technology collaborations to advance instrument ... more
Bruker announces acquisition of a spin-off from Ghent University
Acquisition expands nuclear molecular imaging portfolio
Bruker Corporation announced the acquisition of MOLECUBES NV, a dynamic innovator in benchtop preclinical nuclear molecular imaging (NMI) systems. This acquisition strengthens Bruker’s position as a leading NMI solutions provider in preclinical and translational imaging research.
The combination of Bruker’s preclinical imaging products and global footprint with the modular benchtop CUBES™ systems of MOLECUBES will provide a broader NMI offering to further accelerate worldwide adoption of preclinical NMI in academic medical centers and biopharma companies.
Dr. Wulf I. Jung, President of the Bruker BioSpin Preclinical Imaging Division commented: “Nuclear molecular preclinical and translational imaging research are growing market segments, in which we are already recognized for high-performance simultaneous PET/MR and PET/SPECT/CT instruments, and for our PMOD™ PET data analysis software. The acquisition of MOLECUBES adds scalable benchtop instruments to our portfolio for serving the NMI preclinical research community. The synergies between our and MOLECUBES’ research and development, applications and service teams is expected to benefit our combined NMI customers worldwide.”
Professor Roel Van Holen, CEO of MOLECUBES, added: “The MOLECUBES vision has always centered around making in vivo NMI available to every lab, by developing small footprint imagers without compromising on image quality. The high throughput of our unique scalable technology makes it an excellent tool to speed up drug discovery and translational research. Bruker has the reach to increase access to the CUBES in labs throughout the world, aligning with our joint mission to support the quality and speed of preclinical drug development and fundamental pathobiology research. Our team is looking forward to working within Bruker on research and innovative solutions for our existing and future customers.”
As a fast-growing company founded in 2015 in Ghent, Belgium, MOLECUBES develops and sells high-end PET, SPECT, and CT CUBES™ systems, with a global installated base of more than 70 systems among key opinion leaders. The modular benchtop CUBES complement Bruker’s integrated, floor-standing preclinical small animal imaging systems.
MOLECUBES will remain an innovative and agile operational team within the Bruker BioSpin Preclinical Imaging division, and MOLECUBES customers can continue communications through existing channels. MOLECUBES’ R&D and applications teams will collaborate with Bruker’s preclinical imaging experts to continuously advance NMI technology, software, workflows and applications.
MOLECUBES generated approximately Euro 5 million in FY 2020 revenue. Financial details of the acquisition were not disclosed.
- molecular imaging systems
- in vivo imaging
Bruker Corporation announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022. Dr. Ma is Chief Executive Officer, founder, and a director of PrognomiQ, a privately held healthcare company that is developing next-generation, tran ... more
Bruker Corporation announced the acquisition of Prolab Instruments GmbH, a Swiss technology company specialized in low-flow, high precision liquid chromatography technology and systems. Financial terms of the transaction were not disclosed. Mr. Werner Doebelin, the Founder and CEO of Prolab ... more
Diffraction limited high sensitivity (FT-)IR microscopy and imaging at maximum speed ✓ Infrared laser imaging in all measurement modes (ATR, Transmission, Reflectance) ✓ Coherence reduction for artifact free Laser Imaging measurements without sensitivity or speed loss ✓ more
IR spectrometer for research and demanding analysis ✓ The world's most advanced interferometer & detector technology ✓ 100% designed for reliability, productivity and highest data quality ✓ more
Maximum Flexibility: The MPA II is custom-build for you to match your very own application needs ✓ Easy Operation: Even untrained personnel can use the MPA II spectrometer from day one ✓ Green Technology: By saving energy and chemicals, the MPA II can reduce your ecological footprint ✓ more
- 1Miniaturized Lab-on-a-Chip for real-time Chemical Analysis of Liquids
- 2Organic thin-film sensors for light-source analysis and anti-counterfeiting applications
- 3A new era of early cancer detection with blood test may change cancer screening paradigms
- 4Beckman Coulter Life Sciences acquires Dublin biotech start-up
- 5Less risk, less costs: Portable spectroscopy devices could soon become real
- 6Pumping up the music of molecules
- 7Mobile phone app accurately detects COVID-19 infection in people’s voices with the help of artificial intelligence
- 8Show me your brain scan and I'll tell you how old you really are
- 9Early Detection by Tango
- 10Sensing pressure using paper